<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-37102-2S4</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">A novel gene therapy approach to cure HIV</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">Despite the potency of current anti-HIV drugs, the patient is never cured, necessitating life-long treatment, potentially with adverse effects and the risk of drug-resistance. Inspired by the Berlin patient, gene therapies were proposed as single treatment to achieve a permanent state of virus suppression. Recent in vitro experiments demonstrate that such a sterilizing cure can be reached with the CRISPR-Cas reagents. An important bottleneck that has to be dealt with is the low efficiency of the delivery vector. To address this major bottleneck, we here propose to develop an all-in-one vector with a high titer to facilitate such curative strategies.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">HIV drugs are effective at reducing the viral load in patients and to block disease progression, but do not lead to a cure because the virus is only suppressed and not inactivated. Therefore durable gene therapy approaches are being developed in which the virus is inactivated, which would require a single treatment. Several studies demonstrated that a novel anti-HIV approach based on the CRISPRCas9 technique can effectively inactivate HIV in cells. However, for the delivery of the components of this system to all infected cells, novel more-efficient delivery vehicles are needed. The aim of this study is to generate an all-in-one lentiviral vector that will allow efficient delivery. The final goal is permanently inactivate all the virus genomes that are present in all infected cells.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Our main goal is to eliminate or permanently inactivate the proviral DNA in every infected cell, thus curing HIV-1 infected individuals. To reach all infected cells, an efficient delivery vehicle for the anti-viralsis required. By fitting all components required  for such a curative intervention in a single small lentiviral vector, we expect to generate a significantly more efficient delivery vehicle, which will spur the
development of an in vivo gene therapy application to directly target cells of the HIV latent reservoir.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">Those HIV-infected individuals that fail on available drug therapy and those that have difficulties to comply with these drug regimens.</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="4" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2018-10-15" type="2"></activity-date>
  <activity-date iso-date="2020-03-14" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2018-10-15"></period-start>
   <period-end iso-date="2020-03-14"></period-end>
   <value currency="EUR" value-date="2018-10-15">75000</value>
  </budget>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-01-01"></transaction-date>
   <value currency="EUR" value-date="2017-01-01">10258</value>
   <description>
    <narrative xml:lang="EN">2nd disbursement period jan-june 2017</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">NAFOPHANU</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-07-21"></transaction-date>
   <value currency="EUR" value-date="2017-07-21">28539</value>
   <description>
    <narrative xml:lang="EN">3rd Disbursement</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">NAFOPHANU</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-09-19"></transaction-date>
   <value currency="EUR" value-date="2016-09-19">89421</value>
   <description>
    <narrative xml:lang="EN">Commitment to 31-12-2017 (excl inception commitment 3.000)</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">NAFOPHANU</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-08-16"></transaction-date>
   <value currency="EUR" value-date="2016-08-16">5258</value>
   <description>
    <narrative xml:lang="EN">First disbursement budget 2016</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">NAFOPHANU</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">6853</value>
   <description>
    <narrative xml:lang="EN">Opbrengst ADD 2018 voor High Risk High Gain Onderzoek: &#x20AC;136.293 

Gelijk verdeeld over dit project en P-37102 (A novel gene therapy approach to cure HIV); 

 

bijdrage AmsterdamDiner Foundation aan P-37204 &#x20AC;68.146,50

bijdrage Aidsfonds aan P-37204 &#x20AC;6853,50</narrative>
   </description>
   <provider-org provider-activity-id="NL-KVK-41207989-" ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-10-21"></transaction-date>
   <value currency="EUR" value-date="2016-10-21">36984</value>
   <description>
    <narrative xml:lang="EN">Second disbursement budget 2016</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">NAFOPHANU</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-01-19"></transaction-date>
   <value currency="EUR" value-date="2018-01-19">14002</value>
   <description>
    <narrative xml:lang="EN">contract 2018 commitment</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">NAFOPHANU</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-04-04"></transaction-date>
   <value currency="EUR" value-date="2016-04-04">263</value>
   <description>
    <narrative xml:lang="EN">paid in cash</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">NAFOPHANU</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">67500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">67500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-08-25"></transaction-date>
   <value currency="EUR" value-date="2020-08-25">7500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-08-25"></transaction-date>
   <value currency="EUR" value-date="2020-08-25">3547</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-08-26"></transaction-date>
   <value currency="EUR" value-date="2020-08-26">3547</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2018-05-31"></transaction-date>
   <value currency="EUR" value-date="2018-05-31">68147</value>
   <provider-org provider-activity-id="NL-KVK-412115640001-" ref="NL-KVK-412115640001">
    <narrative xml:lang="EN">AmsterdamDiner Foundation</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-34501-2S4" type="1"></related-activity>
 </iati-activity>
</iati-activities>
